Anhydramnios is the virtual or complete absence of amniotic fluid surrounding a fetus, and it represents one of the most serious findings on prenatal ultrasound. Unlike milder reductions in fluid (oligohydramnios), anhydramnios leaves no measurable pocket of fluid at all, which has direct consequences for fetal lung development, limb positioning, and the ability to even visualize the fetus clearly on imaging. The prognosis depends heavily on what is causing the fluid loss and when it starts, but outcomes historically have been grim when the condition sets in early in pregnancy and persists.
What Causes Anhydramnios
Amniotic fluid is mostly produced by fetal urine during the second and third trimesters, so anything that shuts down fetal urine output or allows fluid to leak out of the uterus can cause anhydramnios. The causes break down into a few broad categories, each with very different implications for prognosis.
Kidney and Urinary Tract Abnormalities
The most severe category involves structural problems with the fetal kidneys or urinary tract. Bilateral renal agenesis, where both kidneys fail to form, is a classic cause. Because the fetus produces no urine, there is no mechanism to maintain fluid volume. This condition leads to anhydramnios and the resulting lung underdevelopment that has historically been fatal shortly after birth.1SpringerLink / Pediatr Nephrol. Bilateral renal agenesis: fetal intervention and outcomes Other renal malformations, such as bilateral multicystic dysplastic kidneys or severe lower urinary tract obstruction (where urine is produced but cannot exit the bladder), can have the same downstream effect. A 2018 NIH workshop summary noted that anhydramnios in the setting of severe fetal kidney and urinary tract malformations carries a high rate of stillbirth and life-threatening complications including pulmonary hypoplasia, cord compression, and perinatal asphyxia.2PubMed Central. Anhydramnios in the Setting of Renal Malformations: The National Institutes of Health Workshop Summary
The condition referred to as early-pregnancy renal anhydramnios, where absent urine output leads to anhydramnios before 22 weeks of gestation, occurs in at least 1 in 2,000 pregnancies and has been considered universally fatal without intervention because the prolonged lack of fluid prevents the lungs from developing enough to support breathing after birth.2PubMed Central. Anhydramnios in the Setting of Renal Malformations: The National Institutes of Health Workshop Summary
Preterm Premature Rupture of Membranes
The other major cause is preterm premature rupture of membranes (PPROM), where the amniotic sac breaks early and fluid leaks out faster than the fetus can replace it. If the rupture is large or happens at a very early gestational age, the fluid level can drop to zero. A study of preterm infants born after PPROM found that those who had anhydramnios in utero showed elevated kidney function markers (serum creatinine) even weeks after birth, suggesting the lack of fluid has effects beyond just the lungs.3PubMed. Postnatal serum creatinine is elevated in preterm infants with PPROM-induced anhydramnios Researchers have also specifically examined how residual anhydramnios after PPROM affects respiratory distress syndrome, since the concern is that even if the membranes rupture for a non-renal reason, the prolonged absence of fluid still impairs lung growth.4Perinatal Journal. Evaluation of the impact of residual anhydramnios following preterm premature rupture of membranes on respiratory distress syndrome
When membranes rupture before 21 weeks, survival is especially poor. In one study, only 3 of 26 infants survived when rupture occurred before week 21, compared with 4 of 10 when it occurred between weeks 21 and 23.5PubMed. Premature rupture of membranes with oligo- or anhydramnios before 24 weeks of gestation and the chances of fetal survival Those few extra weeks of lung development make a meaningful difference.
Medications That Reduce Fetal Urine Output
Certain drugs taken during pregnancy can cause the fetal kidneys to temporarily shut down, leading to anhydramnios that is sometimes reversible once the medication is stopped. Non-steroidal anti-inflammatory drugs (NSAIDs) are one documented culprit; in at least one case, fetal anhydramnios resolved after the mother stopped taking the medication, with no lasting harm to the newborn.6PubMed Central. Fetal anhydramnios following maternal non-steroidal anti-inflammatory drug use in pregnancy
Blood pressure medications that act on the renin-angiotensin system, including ACE inhibitors and angiotensin receptor blockers (ARBs), are a well-known concern. These drugs can impair fetal kidney function and cause severe reductions in amniotic fluid. One case report described anhydramnios at 30 weeks in a woman taking valsartan, an ARB.7PubMed Central. Reversible Fetal Renal Impairment following Angiotensin Receptor Blocking Treatment during Third Trimester of Pregnancy: Case Report and Review of the Literature Another report documented severe oligohydramnios along with abnormalities of the fetal skull and other structures after prolonged ACE inhibitor exposure starting early in pregnancy.8PubMed. Pregnancy with prolonged fetal exposure to an angiotensin-converting enzyme inhibitor These drug-induced cases differ fundamentally from structural kidney problems because the underlying organs may be normal, and stopping the offending medication can sometimes allow fluid to reaccumulate.
Why the Lungs Are the Central Problem
Amniotic fluid is not just cushioning. During the second and third trimesters, the fetus breathes it in and out of its developing lungs. This fluid movement physically stretches the lung tissue and stimulates growth. Without it, the lungs remain small and stiff, a condition called pulmonary hypoplasia. When the lungs are severely underdeveloped at birth, the infant cannot exchange oxygen and carbon dioxide well enough to survive.
Research on pregnancies complicated by early-pregnancy renal anhydramnios has shown that the degree of pulmonary hypoplasia correlates with how long the fetus goes without fluid. In other words, a fetus that has had zero amniotic fluid for 15 weeks will generally have worse lung development than one with zero fluid for 5 weeks.9PubMed Central. Pulmonary hypoplasia correlates with the length of anhydramnios in patients with early pregnancy renal anhydramnios (EPRA) This finding has practical importance: it suggests that any intervention to restore fluid should start as early as possible, because every additional week without amniotic fluid worsens the lung outcome.
Other Physical Complications
Besides the lungs, prolonged anhydramnios causes a constellation of physical findings sometimes grouped under the term Potter sequence. Without fluid to move in, the fetus is compressed against the uterine wall. This can produce characteristic facial features (flattened nose, recessed chin, low-set ears), limb contractures from being held in one position, and skeletal deformities. In extreme cases, abnormal fusion of structures can occur; one case report described sirenomelia (fused lower limbs), absent external genitalia, absent anal opening, and the characteristic Potter facies in a fetus with anhydramnios.10Journal of Diagnostic Medical Sonography. Sirenomelia With Anhydramnios: A Clue From the Movements of Fetal Limbs
Umbilical cord compression is another risk. With no fluid buffer between the cord and the fetus or uterine wall, the cord can be squeezed during fetal movement or contractions, cutting off blood flow. This contributes to the elevated stillbirth rate seen in these pregnancies.
Diagnosis When You Cannot See the Fetus Clearly
Anhydramnios creates a diagnostic paradox: the very condition that demands a detailed anatomical survey of the fetus makes that survey almost impossible. Without amniotic fluid to provide acoustic contrast, ultrasound images are often too poor to identify exactly what structural abnormalities are present. In one series of 61 pregnancies with severe oligohydramnios or anhydramnios, roughly 60% had no ultrasound findings at all before intervention, simply because the images were unreadable.11PubMed. Impact of antepartum diagnostic amnioinfusion on targeted ultrasound imaging of pregnancies presenting with severe oligo- and anhydramnios: An analysis of 61 cases
To work around this, clinicians can perform a diagnostic amnioinfusion, injecting sterile fluid into the uterus through a needle to temporarily restore the fluid environment. In that same series, the deepest fluid pocket jumped from an average of 0.6 centimeters before the procedure to 3.4 centimeters afterward, and the detection of fetal abnormalities increased substantially.11PubMed. Impact of antepartum diagnostic amnioinfusion on targeted ultrasound imaging of pregnancies presenting with severe oligo- and anhydramnios: An analysis of 61 cases A separate retrospective study confirmed that amnioinfusion improved sonographic visualization and diagnostic accuracy in most cases.12PubMed Central. Prenatal Amnioinfusion as a Diagnostic Tool in Severe Oligo- and Anhydramnios: A Retrospective Single-Center Experience with Descriptive Perinatal Outcomes Getting the diagnosis right matters enormously, because management changes completely depending on whether the fetus has absent kidneys versus a urinary tract blockage versus normal kidneys with ruptured membranes.
What Gestational Age Means for Survival
Timing is the single most important prognostic variable in anhydramnios. When it develops early, before about 22 weeks, the lungs have a long stretch of development still ahead and almost no fluid to support it. This is the scenario described in early-pregnancy renal anhydramnios, which without treatment has been considered uniformly lethal.2PubMed Central. Anhydramnios in the Setting of Renal Malformations: The National Institutes of Health Workshop Summary
When anhydramnios develops later, outcomes improve. A small study of six cases where anhydramnios appeared after 22 weeks found that the three cases managed without intervention all resulted in neonatal death from pulmonary hypoplasia. But in the two cases where intervention successfully restored amniotic fluid, the neonates survived.13PubMed Central. New Anhydramnios after 22 Weeks and Pulmonary Hypoplasia Numbers this small do not prove anything on their own, but the pattern is consistent with what the lung development data predicts: less time without fluid means better lung growth and a better shot at breathing after birth.
Anhydramnios that sets in during the third trimester, after the lungs have already undergone most of their branching and growth, carries a fundamentally different prognosis. While it can still cause complications such as cord compression or abnormal fetal positioning, the risk of lethal pulmonary hypoplasia drops considerably because the critical window of lung development has already largely passed.
Serial Amnioinfusion as Treatment
The most dramatic shift in the management of anhydramnios in recent years involves serial amnioinfusions for pregnancies where the fetus has no functioning kidneys. Rather than using a single injection of fluid for diagnostic purposes, clinicians perform repeated amnioinfusions throughout the pregnancy to keep amniotic fluid present and give the fetal lungs a chance to develop.
The landmark Renal Anhydramnios Fetal Therapy (RAFT) trial tested this approach in fetuses with bilateral renal agenesis. Among the 18 pregnancies in the amnioinfusion group, 17 resulted in live births at a median gestational age of about 32 and a half weeks. Of those 17 live-born infants, 14 (about 82%) survived to at least 14 days of life and had dialysis access placed, meaning they were alive and on the path toward long-term kidney replacement therapy.14JAMA. Neonatal Survival After Serial Amnioinfusions for Bilateral Renal Agenesis: The Renal Anhydramnios Fetal Therapy Trial For a condition that was previously considered 100% fatal, those numbers are remarkable.
A systematic review of serial amnioinfusion therapy for bilateral renal agenesis across multiple studies tempered the optimism somewhat, noting that while the procedure improves the chances of surviving the first days to weeks, survival beyond that early window is not yet consistent.15PubMed Central. Serial Amnioinfusion Therapy for Treatment of Congenital Bilateral Renal Agenesis—A Systematic Review These infants face a lifetime of dialysis and eventual kidney transplant, and the burden of renal failure in the neonatal period is immense. Still, the fact that some infants are surviving to transplant has fundamentally changed the counseling conversation for families.
Interventions for Urinary Tract Obstruction
When anhydramnios is caused not by absent kidneys but by a physical blockage preventing urine from exiting the bladder, a different set of interventions comes into play. Vesicoamniotic shunting involves placing a small tube through the fetal abdominal wall and into the bladder, allowing urine to drain directly into the amniotic space. Fetal cystoscopy, where a tiny camera is passed into the fetal bladder to directly treat the obstruction, is an alternative approach.
A meta-analysis comparing the two techniques found that they carry similar rates of complications and outcomes. The incidence of fetal death in utero, postnatal death, and postnatal kidney impairment did not differ significantly between shunting and cystoscopy. Both procedures were burdened by similar rates of infection, membrane rupture, premature birth, and abdominal wall complications.16PubMed. Fetal Cystoscopy and Vesicoamniotic Shunting in Lower Urinary Tract Obstruction: A Meta-Analysis of Long-Term Outcome and Current Technical Limitations The shunt approach has one known weakness: dislodgement. In at least one reported case, a shunt that became dislodged led to persistent anhydramnios and neonatal death, while successful shunt or intervention in other cases resulted in survival.13PubMed Central. New Anhydramnios after 22 Weeks and Pulmonary Hypoplasia Early shunting may reduce the burden of kidney damage, though the evidence remains limited.17PubMed Central. Postnatal Management in Congenital Lower Urinary Tract Obstruction With and Without Prenatal Vesicoamniotic Shunt
Can Maternal Hydration Help
For milder fluid reductions (oligohydramnios), increasing the mother’s water intake has been studied as a simple, noninvasive strategy. A Cochrane review found that asking women with oligohydramnios to drink two liters of water led to a measurable increase in amniotic fluid volume, and that intravenous hypotonic fluids also raised fluid levels, while isotonic intravenous fluids did not.18PubMed. Maternal hydration for increasing amniotic fluid volume in oligohydramnios and normal amniotic fluid volume A more recent meta-analysis suggested that oral hydration with hypotonic (plain water) solutions at about 1,500 milliliters per day over two weeks appeared to be the most effective and practical approach.19PubMed Central. An Update on Maternal Hydration Strategies for Amniotic Fluid Improvement in Isolated Oligohydramnios and Normohydramnios: Evidence from a Systematic Review of Literature and Meta-Analysis
There is an important caveat here: these studies were conducted in women with oligohydramnios, not anhydramnios. If the cause of absent fluid is that the fetus has no kidneys or a complete urinary blockage, drinking more water will not help because the fetal kidneys are not able to convert maternal hydration into urine. Maternal hydration is potentially useful when low fluid is caused by reduced blood flow to the placenta or mild dehydration, but it does not address the structural causes of true anhydramnios.
The Diagnostic Gap
One frustration that runs through the literature on anhydramnios is the lack of reliable prognostic tools. The NIH workshop summary stated plainly that available diagnostic methods do not provide reliable prognostic information for anhydramnios in the setting of renal malformations, and that current interventions have not been standardized.2PubMed Central. Anhydramnios in the Setting of Renal Malformations: The National Institutes of Health Workshop Summary This means that when families receive the diagnosis, clinicians often cannot tell them with confidence whether a given fetus will have lungs developed enough to survive, or whether the kidneys have any residual function worth preserving. Fetal MRI and biochemical analysis of fetal urine have been used in some centers, but neither has been validated well enough to serve as a reliable predictor across the board.
This diagnostic uncertainty makes decision-making particularly wrenching for families. Some choose to pursue aggressive intervention knowing the odds remain unclear. Others choose comfort care, focusing on the time they will have with their infant after birth. Both paths are medically reasonable given how thin the evidence base still is for many scenarios.
How Palliative Care Fits In
Even as new interventions push the boundaries of what is survivable, palliative care remains a critical part of managing pregnancies complicated by anhydramnios. The emergence of serial amnioinfusions has not eliminated the need for palliation; if anything, it has made the care more complex. An infant who survives birth thanks to amnioinfusions but then faces months of dialysis, multiple surgeries, and an uncertain path to transplant needs coordinated support for pain management, family coping, and medical decision-making throughout. One report from the American Academy of Pediatrics described the role of palliative care across the full arc of care for an infant with bilateral renal agenesis who was treated with prenatal amnioinfusions, emphasizing that the shifting paradigm from “lethal diagnosis” to “potentially treatable condition” creates new layers of complexity rather than simply removing the old ones.20American Academy of Pediatrics (Pediatrics). Bilateral Renal Agenesis: Redefining Complex Palliative Care Across the Continuum of a Shifting Disease Paradigm
Artificial Placenta Research
Looking further ahead, researchers have explored the concept of an artificial placenta that would use extracorporeal life support to sustain extremely premature or compromised infants outside the womb in a fluid-filled environment that mimics the uterus.21PubMed Central. A paradigm shift in the treatment of extreme prematurity: the artificial placenta While this technology has primarily been investigated as a way to improve outcomes for extremely premature infants, its theoretical relevance to anhydramnios is clear: if an artificial fluid environment can support lung development outside the body, it might eventually offer another avenue for fetuses whose lungs cannot develop normally in utero. This remains firmly in the laboratory stage, and no clinical application for anhydramnios specifically is imminent. But it reflects the broader trajectory of fetal medicine, which has been steadily expanding the range of conditions it can intervene in before birth, and the interest in doing so for conditions that were until recently considered beyond help.